<DOC>
	<DOCNO>NCT01751906</DOCNO>
	<brief_summary>The ABSORB III RCT prospective randomize , single-blind , multi-center trial . It pivotal trial support US pre-market approval ( PMA ) Absorb™ Bioresorbable Vascular Scaffold ( BVS ) . The ABSORB III include additional two trial i.e . ABSORB III PK ( pharmacokinetics ) sub-study ABSORB IV RCT trial maintain one protocol trial design relate , ABSORB IV continuation ABSORB III data ABSORB III ABSORB IV pool support ABSORB IV primary endpoint . Both trial evaluate safety effectiveness Absorb BVS .</brief_summary>
	<brief_title>ABSORB III Randomized Controlled Trial ( RCT )</brief_title>
	<detailed_description>ABSORB III RCT : A . Primary Objective : The pivotal trial support US pre-market approval ( PMA ) Absorb BVS . ABSORB III evaluate safety effectiveness Absorb BVS System compare XIENCE treatment subject , include diabetes mellitus , ischemic heart disease cause two de novo native coronary artery lesion separate epicardial vessel . B. Powered Secondary Objectives : 1 . Lead-In Phase Objective : To evaluate applicability transferability didactic Absorb BVS physician training plan US clinical practice . The lead-in phase non-randomized , single-arm , open label group 50 subject treat Absorb BVS 35 US site . The Lead-In phase enroll/register subject prior randomization phase ABSORB III . The Lead-In Phase allow treatment two de novo native coronary artery lesion different epicardial vessel reference vessel diameter ( RVD ) ≥ 2.75 mm ≤ 3.25 mm lesion length ≥ 8 ≤ 14 mm . 2 . Imaging Cohort Objective : To evaluate long-term vascular function patency Absorb BVS treat segment compare XIENCE treated segment treatment subject ischemic heart disease cause two de novo native coronary artery lesion separate epicardial vessel . The image cohort-phase prospective , randomize ( 2:1 Absorb BVS XIENCE ) , single-blind , multi-center trial , register approximately 200 subject . This include 150 subject angiographic/intravascular ultrasound ( IVUS ) endpoints analysis approximately 50 subject optical coherence tomography ( OCT ) endpoints analysis . The 200 subject separate 2000 subject include primary analysis . Data two power secondary endpoint cohort support label claim superiority Absorb BVS compare XIENCE specific vasomotion late lumen enlargement . All subject ABSORB III unless specify receive treatment two de novo native coronary artery lesion different epicardial vessel RVD ≥ 2.5 mm ≤ 3.75 mm lesion length ≤ 24 mm .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General 1 . 18 year age . 2 . Subject legally authorize representative must provide write Informed Consent prior study related procedure , per site requirement . 3 . Subject must evidence myocardial ischemia . In absence noninvasive ischemia , fractional flow reserve ( FFR ) must do indicative ischemia . 4 . Acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Female subject childbearing potential plan pregnancy 1 year follow index procedure . For female subject childbearing potential pregnancy test must perform negative result know within 7 day prior index procedure per site standard . 6 . Female subject breastfeeding time screen visit breastfeed 1 year follow index procedure . 7 . Subject agree participate investigational invasive clinical study period 1 year follow index procedure . General 1 . Any surgery require general anesthesia discontinuation aspirin and/or adenosine diphosphate ( ADP ) antagonist plan within 12 month procedure . 2 . Hypersensitivity contraindication device material degradants ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) cobalt , chromium , nickel , platinum , tungsten , acrylic fluoro polymer adequately premedicated . Subject know contrast sensitivity adequately premedicated . 3 . Allergic reaction , hypersensitivity contraindication aspirin ; clopidogrel prasugrel ticagrelor ; heparin bivalirudin , therefore adequately treat study medication . 4 . Acute myocardial infarction ( AMI : STEMI NSTEMI ) within 72 hour index procedure creatine kinase ( CK ) CKMB return within normal limit time index procedure ; subject stable angina silent ischemia CKMB great normal limit time index procedure . 5 . Subject currently experience clinical symptom consistent new onset AMI ( STEMI NSTEMI ) , nitrateunresponsive prolong chest pain ischemic ECG change . 6 . Cardiac arrhythmia identify time screen least one follow criterion meet : ( NOTE : Investigator use discretion enrol subject high CHADS score ) 1 . Subject require coumadin agent chronic oral anticoagulation 2 . Subject likely become hemodynamically unstable due arrhythmia 3 . Subject poor survival prognosis due arrhythmia 7 . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . 8 . Subject undergone prior percutaneous coronary intervention ( PCI ) within target vessel last 12 month . Prior PCI within nontarget vessel peripheral intervention acceptable perform anytime &gt; 30 day index procedure , 24 hour 30 day index procedure successful uncomplicated . 9 . Future stag PCI either target nontarget vessel subject require future peripheral intervention &lt; 30 day index procedure . 10 . Subject receive solid organ transplant wait list solid organ transplant . 11 . At time screening , subject malignancy remission . 12 . Subject receive immunosuppressant therapy know immunosuppressive severe autoimmune disease require chronic immunosuppressive therapy ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. ) . Note : corticosteroid include immunosuppressant therapy . 13 . Subject previously receive schedule receive radiotherapy coronary artery ( vascular brachytherapy ) , chest/mediastinum . 14 . Subject receive require chronic anticoagulation therapy ( e.g. , coumadin , dabigatran , apixaban , rivaroxaban agent reason ) . 15 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 16 . Subject document suspected hepatic disorder define cirrhosis ChildPugh ≥ Class B . 17 . Renal insufficiency . NOTE : Estimated glomerular filtration rate ( GFR ) base Modification Diet Renal Disease ( MDRD ) equation CockcroftGault equation ( CCG ) . 18 . High risk bleed reason ; history bleed diathesis coagulopathy ; significant gastrointestinal significant urinary bleed within past six month . 19 . Cerebrovascular accident transient ischemic neurological attack ( TIA ) within past six month , prior intracranial bleed , permanent neurologic defect , know intracranial pathology ( e.g. , aneurysm , arteriovenous malformation , etc. ) . 20 . Extensive peripheral vascular disease precludes safe 6 French sheath insertion . Note : femoral arterial disease exclude patient radial access may use . 21 . Subject life expectancy &lt; 5 year noncardiac cause cardiac cause . 22 . Subject opinion Investigator designee , unable comply requirement study protocol unsuitable study reason . This include completion Patient Reported Outcome instrument . 23 . Subject currently participate another clinical trial yet complete primary endpoint . 24 . Vulnerable population . Angiographic 1 . One two de novo target lesion : 1 . If one target lesion , second nontarget lesion may treat nontarget lesion must present different epicardial vessel , must treat first successful , uncomplicated result prior randomization target lesion . 2 . If two target lesion present , must present different epicardial vessel must satisfy angiographic eligibility criterion . 3 . The definition epicardial vessel mean LAD , LCX RCA branch . Thus , patient must lesion require treatment e.g . LAD diagonal branch . 2 . Target lesion ( ) must locate native coronary artery visually estimate quantitatively assess % diameter stenosis ( DS ) ≥ 50 % &lt; 100 % thrombolysis myocardial infarction ( TIMI ) flow ≥1 one following : stenosis ≥ 70 % , abnormal functional test ( e.g . fractional flow reserve , stress test ) , unstable angina postinfarct angina . 1 . Lesion ( ) must locate native coronary artery RVD visual estimation ≥ 2.5 mm ≤ 3.75 mm . 2 . Lesion ( ) must locate native coronary artery length visual estimation ≤ 24 mm . 3 . For LeadIn subject 3.0x18 mm Absorb BVS : lesion ( ) must locate native coronary artery RVD visual estimation ≥ 2.75 mm ≤ 3.25 mm . The lesion length visual estimation ≥ 8 mm ≤ 14 mm . Angiographic All exclusion criterion apply target lesion ( ) target vessel ( ) . 1 . Lesion prevents successful balloon predilatation , define full balloon expansion follow outcome : 1 . Residual % DS maximum &lt; 40 % ( per visual estimation ) , ≤ 20 % strongly recommend . 2 . TIMI Grade3 flow ( per visual estimation ) . 3 . No angiographic complication ( e.g . distal embolization , side branch closure ) . 4 . No dissection National Heart Lung Blood Institute ( NHLBI ) grade DF . 5 . No chest pain last &gt; 5 minute . 6 . No ST depression elevation last &gt; 5 minute 2 . Lesion locate leave main . 3 . Aortoostial right coronary artery ( RCA ) lesion ( within 3 mm ostium ) . 4 . Lesion locate within 3 mm origin Left Anterior Descending Artery ( LAD ) leave circumflex artery ( LCX ) . 5 . Lesion involve bifurcation : 1. side branch ≥ 2 mm diameter , 2. side branch either ostial nonostial lesion diameter stenosis &gt; 50 % , 3. side branch require dilatation . 6 . Anatomy proximal within lesion may impair delivery Absorb BVS XIENCE stent : 1 . Extreme angulation ( ≥ 90° ) proximal within target lesion . 2 . Excessive tortuosity ( ≥ two 45° angle ) proximal within target lesion . 3 . Moderate heavy calcification proximal within target lesion . If IVUS use , subject must exclude calcium arc vessel prior lesion within lesion ≥ 180° . 7 . Vessel contain thrombus indicate angiographic image IVUS OCT. 8 . Lesion vessel involve myocardial bridge . 9 . Vessel previously treat stent time prior index procedure Absorb BVS XIENCE would need cross stent reach target lesion . 10 . Vessel previously treat target lesion within 5 mm proximal distal previously treat lesion . 11 . Target lesion locate within arterial saphenous vein graft distal arterial saphenous vein graft .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Absorb™ BVS</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Bioabsorbable</keyword>
	<keyword>BVS</keyword>
	<keyword>Bioresorbable</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Artery Endothelial Responsiveness</keyword>
	<keyword>Coronary artery restenosis</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Coronary scaffold</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Stents</keyword>
</DOC>